Thermo Fisher Scientific Inc. (TMO)
| Market Cap | 184.14B |
| Revenue (ttm) | 43.21B |
| Net Income (ttm) | 6.58B |
| Shares Out | 377.61M |
| EPS (ttm) | 17.30 |
| PE Ratio | 28.20 |
| Forward PE | 20.81 |
| Dividend | $1.72 (0.35%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 2,223,666 |
| Open | 487.77 |
| Previous Close | 492.60 |
| Day's Range | 480.95 - 490.07 |
| 52-Week Range | 385.46 - 627.88 |
| Beta | 0.76 |
| Analysts | Buy |
| Price Target | 583.25 (+19.6%) |
| Earnings Date | Oct 22, 2025 |
About TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for phar... [Read more]
Financial Performance
In 2024, Thermo Fisher's revenue was $42.88 billion, an increase of 0.05% compared to the previous year's $42.86 billion. Earnings were $6.34 billion, an increase of 5.67%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for TMO stock is "Buy." The 12-month stock price target is $583.25, which is an increase of 19.60% from the latest price.
News
Thermo Fisher Scientific Inc. (TMO) J.P. Morgan CEO Call Series Call (Transcript)
Thermo Fisher Scientific Inc. J.P. Morgan CEO Call Series September 5, 2025 1:00 PM EDT Company Participants Marc Casper - Chairman, President & CEO Conference Call Participants Rachel Vatnsdal Olson ...
Thermo Fisher Scientific Completes Acquisition of Sanofi's Ridgefield, New Jersey Site
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi's state-of-the-art sterile f...
Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.
Accelerates Solventum's business transformation to deliver long-term shareholder value Net proceeds will be used primarily to pay down debt ST. PAUL, Minn.
Thermo Fisher Scientific Completes Acquisition of Solventum's Purification and Filtration Business
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification...
Thermo Fisher Scientific to Participate in J.P. Morgan CEO Call Series on September 5, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will pa...
Thermo Fisher Scientific Secures R&D 100 Awards for Innovations Accelerating the Discovery and Development of Therapies
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, is proud to receive three R&D 100 Awards for innovations designed to advance scientific discovery i...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
ERMA Systems Welcomes Israel Aker, PharmD, RPh, Thermo Fisher Scientific to Advisory Board to Strengthen Medical Affairs Strategy
MIAMI--(BUSINESS WIRE)--ERMA Systems, the AI-powered SaaS company transforming how Life Sciences organizations manage their Promotional and Medical Review Committee (PRC/MRC) processes, proudly announ...
Thermo Fisher Scientific Opens Manufacturing Center of Excellence Site in North Carolina
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its innovative manufacturing center of excellence facility in ...
Thermo Fisher Positioned As Biopharma's Partner Of Choice
Could Thermo Fisher Scientific Inc. TMO be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strat...
Final Trades: Toast, Transdigm, Thermo Fisher and Amazon
The Investment Committee give you their top stocks to watch for the second half.
Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside
Revenue growth is accelerating, led by pharma/biotech momentum and bioproduction demand. The medium-term margin outlook is positive with cost cuts, AI-driven efficiencies, and lapping of tariff headwi...
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test...
Thermo Fisher: The Rerating Is Just Getting Started - Buy
Thermo Fisher is emerging from a challenging period with solid fundamentals, strong cash flow, and renewed growth, making it undervalued by the market. Recent earnings showed organic growth, margin ex...
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...
Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets
I reiterate my Buy rating on Thermo Fisher Scientific Inc., with a fair value estimate of $568 per share, reflecting its undervalued stock price. Q2 FY25 results showed early signs of market recovery,...
Trade tracker: Bill Baruch buys Thermo Fisher
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to explain why he's buying Thermo Fisher here.
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization ...
Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference
WALTHAM, Mass.--(BUSINESS WIRE)--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & ...
Why Thermo Fisher Stock Is Rising Wednesday
Thermo Fisher Scientific Inc. TMO on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23.
Thermo Fisher Scientific Stock Jumps on Strong Results, Higher Outlook
Thermo Fisher Scientific (TMO) shares took off after the maker of lab equipment and other life sciences products posted better-than-expected results and boosted its guidance, citing operational improv...
Thermo Fisher Scientific Inc. (TMO) Q2 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO) Q2 2025 Earnings Conference Call July 23, 2025 8:30 AM ET Company Participants Marc N. Casper - Chairman, President & CEO Rafael Tejada - Vice President of In...
Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial offi...
Thermo Fisher beats quarterly estimates on resilient demand for its tools and services
Thermo Fisher on Wednesday beat Wall Street estimates for second-quarter profit and revenue, helped by steady demand for its products and services used for developing therapies.